Viral load, physical status, and E6/E7 mRNA expression of human papillomavirus in head and neck squamous cell carcinoma

Head and Neck

Volumn 35, Issue 6, 2013, Pages 800-808

  Deng, Zeyi ^a,b   Hasegawa, Masahiro ^a   Kiyuna, Asanori ^a   Matayoshi, Sen ^a   Uehara, Takayuki ^a   Agena, Shinya ^a   Yamashita, Yukashi ^a   Ogawa, Kazuhiko ^a   Maeda, Hiroyuki ^a   Suzuki, Mikio ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

E6 E7 mRNA; head and neck squamous cell carcinoma; human papillomavirus; integration; viral load

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DNA VIRUS; FEMALE; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; PARANASAL SINUS CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TONSIL CARCINOMA; VIRUS LOAD; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; GENES, VIRAL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RNA, MESSENGER; VIRAL LOAD;

EID: 84878013899     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23034     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18: 541-550.
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
4. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
5. Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011; 104: 886-891.
6. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
7. D'souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
8. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007; 117: 2115-2128.
9. Peitsaro P, Johansson B, Syrjänen S,. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002; 40: 886-891.
10. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF,. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006; 102: 54-60.
11. Badaracco G, Venuti A, Sedati A, Marcante ML,. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 2002; 67: 574-582.
12. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM,. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006; 44: 1755-1762.
13. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996; 93: 4350-4354.
14. Serrano M, Hannon GJ, Beach D,. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
15. Jeon S, Lambert PF,. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A 1995; 92: 1654-1658.
16. zur Hausen H,. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 690-698.
17. Koskinen WJ, Chen RW, Leivo I, et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 2003; 107: 401-406.
18. Gillison ML,. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004; 31: 744-754.
19. Lee SY, Cho NH, Choi EC, et al. Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer. Int J Oral Maxillofac Surg 2010; 39: 678-683.
20. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002; 102: 152-158.
21. Specht K, Richter T, Müller U, Walch A, Werner M, Höfler H,. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419-429.
22. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press: 2005.
23. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM,. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987; 61: 962-971.
24. Dürst M, Croce CM, Gissmann L, Schwarz E, Huebner K,. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci U S A 1987; 84: 1070-1074.
25. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-1354.
26. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ,. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76 (Pt 4): 1057-1062.
27. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM,. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell 1989; 7: 209-214.
28. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kühndel K, Liebert UG,. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol 2004; 30: 302-308.
29. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL,. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002; 94: 2199-2210.
30. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002; 98: 590-595.
31. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX,. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 1510-1517.
32. Hoffmann M, Kahn T, Mahnke CG, Goeroegh T, Lippert BM, Werner JA,. Prevalence of human papillomavirus in squamous cell carcinoma of the head and neck determined by polymerase chain reaction and Southern blot hybridization: proposal for optimized diagnostic requirements. Acta Otolaryngol 1998; 118: 138-144.
33. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-2472.
34. Zheng Y, Xia P, Zheng HC, Takahashi H, Masuda S, Takano Y,. The screening of viral risk factors in tongue and pharyngolaryngeal squamous carcinoma. Anticancer Res 2010; 30: 1233-1238.
35. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T,; Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 2009; 39: 850-858.
36. Tsuhako K, Nakazato I, Miyagi J, et al. Comparative study of oral squamous cell carcinoma in Okinawa, Southern Japan and Sapporo in Hokkaido, Northern Japan; with special reference to human papillomavirus and Epstein-Barr virus infection. J Oral Pathol Med 2000; 29: 70-79.
37. Kim SH, Koo BS, Kang S, et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 2007; 120: 1418-1425.
38. De Marco L, Gillio-Tos A, Bonello L, Ghisetti V, Ronco G, Merletti F,. Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. J Clin Virol 2007; 38: 7-13.
39. Hoffmann M, Ihloff AS, Görögh T, et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-1602.
40. Jung AC, Briolat J, Millon R, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 2010; 126: 1882-1894.
41. Ruutu MP, Kulmala SM, Peitsaro P, Syrjänen SM,. The performance of the HPV16 real-time PCR integration assay. Clin Biochem 2008; 41: 423-428.